News | July 26, 2021
Panacea Biotec posts consolidated loss of Rs. 57.35 Cr in Q1FY22
It posted net (loss) of Rs.(34.13) crores for the period ended June 30, 2020.
It posted net (loss) of Rs.(34.13) crores for the period ended June 30, 2020.
The said batches have successfully passed all the checks for quality parameters both at the Gamaleya Center in Russia and at the Central Drug Laboratory, Kasauli in India
The company reported total income of Rs.634.79 crores during the 12 months period ended March 31, 2021
First batch produced at Panacea Biotec’s facilities at Baddi will be shipped to the Gamaleya Center for quality control and full scale production of the vaccine is due to start this summer
These licenses are given in areas of infectious disease diagnostics, immunodiagnostics, and vaccine development
He has previously served in pivotal HR leadership roles at RPG Life Sciences, Akumentis Healthcare, and Wockhardt
“One Earth, One Health” vision can become a reality only with active global collaboration where countries don’t think of only themselves, but of collective global outcomes
Witnessing sizable consolidation (M& A) activity with Domestic Formulations and Hospitals being two areas wherein maximum M&A has occurred.
This is the ninth Covid-19 vaccine approved in India
Sputnik M is a new member of the Sputnik vaccines family
Subscribe To Our Newsletter & Stay Updated
